Compare · ARGX vs HRMY
ARGX vs HRMY
Side-by-side comparison of argenx SE (ARGX) and Harmony Biosciences Holdings Inc. (HRMY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ARGX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while HRMY focuses on Biotechnology: Pharmaceutical Preparations.
- ARGX is the larger of the two at $58.81B, about 30.3x HRMY ($1.94B).
- ARGX has been more active in the news (6 items in the past 4 weeks vs 5 for HRMY).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Harmony Biosciences Holdings Inc.
- Price
- -
- -
- Market cap
- $58.81B
- $1.94B
- 1M return
- +14.67%
- -
- 1Y return
- +3.10%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE
Latest HRMY
- SEC Form SCHEDULE 13G filed by Harmony Biosciences Holdings Inc.
- SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
- Amendment: SEC Form 8-K/A filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Ladenburg Thalmann initiated coverage on Harmony Biosciences with a new price target
- SEC Form 8-K filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
- Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days